Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at firstname.lastname@example.org and follow @DamianFierce on Twitter.
Articles by Damian Garde
German-headquartered CRO Accovion is expanding its reach in Europe, opening a new shop in Italy and planning to launch a French subsidiary in the fall.
Indian CRO GVK Biosciences has spent the last year transitioning from a discovery-focused contractor to a full-service developer, now launching a dedicated clinical research unit to reach drugmakers around the world.
CRO Theorem Clinical Research has inked a deal with India's Excel Life Sciences to broaden its footprint in the country, expanding its access to clinical trial sites and bolstering its patient-recruitment capabilities.
Months removed from getting bought by Huntingdon Life Sciences, Harlan Laboratories has teamed up with a French CRO to expand its capabilities in drug discovery and translational medicine.
Chiltern has acquired Ockham, a fellow contract researcher, planning to absorb the company's capabilities and expand its service offerings.
Pharma contracting giant Catalent has jumbo-sized its Wall Street ambitions, filing to go public in an IPO that would bring in about $872 million at its midpoint.
Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.
The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.
Russia is striving to produce domestically 50% of the drugs sold in the country, and, to do so, it's encouraging global manufacturers to buy, build or rent facilities there.
CRO inVentiv Health has agreed to share its expertise with the nonprofit Alliance for Clinical Research Excellence and Safety (ACRES), working to develop global standards for clinical trials.